LAMISIL
LOE ApproachingNDATOPICALCREAM
Approved
Dec 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
2/8 — Basic
Drug data last refreshed 15h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LAMISIL (terbinafine) is a topical antifungal cream approved in 1992 for dermatological fungal infections. It works by inhibiting fungal cell membrane synthesis through squalene epoxidase inhibition. The product is indicated for topical treatment of fungal skin conditions including tinea pedis, tinea cruris, and tinea corporis.
LOE Approaching
As LOE approaches, the brand team likely operates in maintenance mode with focus on line extensions, OTC variants, or transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Fed Study of Terbinafine Hydrochloride Tablets 250 mg and Lamisil® 250 mg
Started Feb 2004
36 enrolled
Healthy
Fasting Study of Terbinafine Hydrochloride Tablets 250 mg and Lamisil® Tablets 250 mg
Started Feb 2004
36 enrolled
Healthy
Safety and Effectiveness of Giving Lamisil to HIV-Positive Subjects With Thrush Who Have Not Responded to Fluconazole Treatment
30 enrolled
Candidiasis, OralHIV Infections
Career Relevance
LAMISIL offers limited career growth given its LOE-approaching status and minimal linked job openings; opportunities exist primarily in defensive brand management, OTC channel optimization, or portfolio support roles. Professionals seeking dynamic product launches or expansion pipelines should consider other Novartis assets.
Worked on LAMISIL at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.